drugset / Trial / NCT03782636
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
Phase 2
Active not recruiting
41 enrolled
University of Oxford
Centre for Statistics in Medicine, Oxford · collabJuvenile Diabetes Research Foundation · collabOxford Clinical Trials Research Unit (OCTRU) · collabWellcome Trust · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.
Timeline
- Start
- 2019-01-28
- Primary completion
- 2023-02-16
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 0.2 unknown | Subcutaneous |